Immuron Ltd — Board/Management Information 2015

Aug 24, 2015

==> picture [257 x 73] intentionally omitted <==

Immuron Appoints New Chief Executive Officer

25 August 2015, Melbourne, Australia: The Board of Immuron Limited (ASX:IMC) are pleased to announce the appointment of the Company’s new Chief Executive Officer (CEO) Mr. Thomas Liquard who will commence on Monday 31[st] August 2015.

Mr Liquard has held various commercialisation, product development and leadership roles with large pharma and biotech companies and holds an MBA from Columbia Business School and a Bachelor of Science degree from the University of Southern California.

From 2013 to 2014, Mr. Liquard was Chief Operating Officer (COO) of major Australian biotech company Alchemia Limited (ASX:ACL) before then becoming CEO of the Company. Throughout his time will Alchemia, Mr Liquard managed a $22M operating budget, brought two major investors onto the register, and led all major business development and corporate development activities for the company.

Prior to joining Alchemia, Mr. Liquard spent seven years with Pfizer in New York, where he held various commercial roles of increasing scope and responsibility. In his most recent role with Pfizer as the Senior Director, Portfolio Development Leader Emerging Markets for the Established Products, Mr. Liquard was pivotal to driving business development (M&A, licensing, partnerships) and internal product development initiatives which involved managing more than 70 opportunities at various stages of execution.

During his tenure at Pfizer, Mr. Liquard also spent three years as a key member of Pfizer’s Established Products US Brands P&L Leadership Team where he engineered the group’s 505(b)(2) investment strategy, culminating in the $700M acquisition of NextWave Pharmaceuticals, Inc. (NextWave), where Mr Liquard led the pre-and post-acquisition integration efforts of NextWave into the existing Pfizer business.

From 2004 to 2007, Mr. Liquard served as a Senior Consultant with the Frankel Group, where he specialised in the life sciences.

Immuron Chairman Dr. Roger Aston welcomed Mr. Liquard adding:

“The Board are very pleased to have Mr. Liquard joining our team as CEO at Immuron, and we feel he will be the right leader to elevate Immuron to its next level and drive our most recent overseas opportunities for both product development and diversified investment. Thomas will be based in New York for the first 12 months of his appointment in order to focus the Company’s activities in this larger market which were recently initiated by the Board.

The US represents a very significant opportunity and having Thomas located in New York will help us maximise the sales of Travelan and more importantly help the market recognise the high value prospects of Immuron when compared to its peer US listed Biotech companies" said Roger Aston.

Suite 1, 1233 High Street www.immuron.com Armadale, Victoria AUSTRALIA 3143 ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

ABN: 80 063 114 045

==> picture [71 x 23] intentionally omitted <==

When discussing his appointment Mr Liquard said:

"I am very excited to join the team at Immuron. The company has developed a novel and broad technology platform that has the potential to yield multiple drug candidates for the treatment and prevention of hard-to-treat diseases, and therefore create substantial shareholder value. Being based in the US over the next few month, will provide Immuron with a great opportunity to accelerate the Company's momentum by leveraging my extensive network, helping grow revenues and expanding the capital base.”

For and on behalf of the Board;

Dr. Roger Aston Chairman

Ph: +61 (0)3 9824 5254

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travellers’ diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).

Page 2 of 2